Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01531374 · ClinicalTrials.gov registry record · NA
Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement
A NA study, sponsored by Medtronic Cardiovascular.
- Completed
- Registry status
- NA
- Development phase
- 2,777
- Enrollment target
NCT01531374 is a NA study that has completed, run by Medtronic Cardiovascular. The registered enrollment target is 2,777 participants.
The verdict
NCT01531374, a NA study, has completed, sponsored by Medtronic Cardiovascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,777 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of the Medtronic CoreValve® System in the treatment of symptomatic severe aortic stenosis in subjects who have a predicted very high risk and high risk for aortic valve surgery.
Interventions
- DEVICE Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,777 participants |
| Start Date | 2012-02-21 |
| Est. Completion | 2019-11-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01531374
The ClinicalTrials.gov registry entry for NCT01531374 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2,777 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiovascular, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI) is the first listed.
NCT01531374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01531374 about?
NCT01531374 is a clinical study titled "Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement". The purpose of the study is to evaluate the safety and efficacy of the Medtronic CoreValve® System in the treatment of symptomatic severe aortic stenosis in subjects who have a predicted very high risk and high risk for aortic valve surgery.
What is the current status of trial NCT01531374?
This trial is currently completed. It is a NA study. The enrollment target is 2,777 participants. The study started on 2012-02-21. Estimated completion is 2019-11-18.
What interventions are being tested in trial NCT01531374?
The interventions under investigation include: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI) (DEVICE).
Who is sponsoring clinical trial NCT01531374?
This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.